ClinicalTrials.Veeva

Menu

Paracetamol Treatment of the Borderline Significant PDA

S

Shaare Zedek Medical Center

Status and phase

Unknown
Phase 2

Conditions

Patent Ductus Arteriosus

Treatments

Drug: Paracetamol drops
Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT02819414
0174-16-SZMC

Details and patient eligibility

About

The therapeutic approach to the patent ductus arteriosus (PDA) in the premature neonate remains controversial. Currently it is generally accepted to treat only hemodynamically significant PDAs. The current investigation aims to study the effect of treatment on PDAs of borderline significance via a prospective, randomized controlled trial of paracetamol in this group.

Full description

In the neonatal intensive care unit of the Shaare Zedek Medical Center, preterm babies <30 wks. GA, are studied echocardiographically on day of life 3-4. Pending parental informed consent, those diagnosed with a PDA of borderline significance will be randomized to receive either paracetamol or placebo for three days, followed by a repeat echocardiogram. If the PDA remains of borderline significance, the treatment will be continued for an additional 4 days (1 week total). Paracetamol levels and liver functions will be assessed after the third day. Babies will be followed until discharge for subsequent PDA pathology; respiratory distress and chronic lung disease [CLD]; necrotizing enterocolitis [NEC]; retinopathy of prematurity [ROP].

The investigators' primary goal is to demonstrate a decrease in the composite outcome of death or severe morbidity chronic lung disease [CLD], as shown by decreased time on supplemental oxygen and assisted ventilation.

Secondary goals:

  • To demonstrate a decrease in subsequently diagnosed hs PDA, including

    • Decrease in the need for subsequent therapy for PDA closure
    • Decrease in surgical PDA ligations
  • To demonstrate a decrease in necrotizing enterocolitis (NEC) and/or ROP with treatment.

  • To demonstrate no adverse effect on blood flow in anterior cerebral, superior mesenteric and renal arteries.

Enrollment

80 estimated patients

Sex

All

Ages

3 to 6 days old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Preterm neonates < 30 weeks' gestational age PDA of borderline significance

Exclusion criteria

  • Infants not deemed likely to survive more than one week Infants with congenital heart malformations Infants with pulmonary hypertension and right to left ductal shunting

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

80 participants in 2 patient groups, including a placebo group

Control Group
Placebo Comparator group
Description:
Treatment with placebo at a volume of 2.25 cc/kg/dose x 4/day to be given with feeds, or in place of feed when baby is receiving \<2 cc/kg/feed.
Treatment:
Other: Placebo
Treatment Group
Active Comparator group
Description:
Treatment with paracetamol drops at 15 mg/kg/dose x 4/day. Drops will be diluted 1:15 in order to reduce osmolality. This will yield a dose of 2.25 ml/kg/dose, to be given with feeds, or in place of feed when baby is receiving \<2 cc/kg/feed.
Treatment:
Drug: Paracetamol drops

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems